Literature DB >> 16774812

TRH therapy in a patient with juvenile Alexander disease.

Keiko Ishigaki1, Yasushi Ito, Yukio Sawaishi, Kayano Kodaira, Makoto Funatsuka, Nozomi Hattori, Kazutoshi Nakano, Kayoko Saito, Makiko Osawa.   

Abstract

Alexander disease is a rare disorder of the central nervous system caused by a de novo mutation in the glial fibrillary acidic protein (GFAP) gene. Unlike the much more common infantile form, the juvenile form is slowly progressive with bulbar, pyramidal and cerebellar signs. Herein, we report a 9-year old Japanese girl suffering from frequent vomiting, slurred speech and truncal ataxia. Juvenile Alexander disease was diagnosed by genetic analysis, which detected a novel GFAP mutation, D360V. We also describe our clinical success in treating this patient with thyrotropin releasing hormone (TRH).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774812     DOI: 10.1016/j.braindev.2006.05.001

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

1.  All in Your Mind? New-Onset Dysphagia in a Previously Healthy Adolescent Child.

Authors:  Jake Sequeira; Douglas Willson; Mark Marinello
Journal:  J Pediatr Intensive Care       Date:  2019-12-05

Review 2.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

Review 3.  Intermediate filaments: primary determinants of cell architecture and plasticity.

Authors:  Harald Herrmann; Sergei V Strelkov; Peter Burkhard; Ueli Aebi
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

4.  Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis.

Authors:  Tomokatsu Yoshida; Masayuki Sasaki; Mari Yoshida; Michito Namekawa; Yuji Okamoto; Seiichi Tsujino; Hiroshi Sasayama; Ikuko Mizuta; Masanori Nakagawa
Journal:  J Neurol       Date:  2011-05-01       Impact factor: 4.849

Review 5.  Strategies for treatment in Alexander disease.

Authors:  Albee Messing; Christine M LaPash Daniels; Tracy L Hagemann
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

6.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

Review 7.  Identification of a novel de novo pathogenic variant in GFAP in an Iranian family with Alexander disease by whole-exome sequencing.

Authors:  Katayoun Heshmatzad; Niloofar Naderi; Tannaz Masoumi; Hamidreza Pouraliakbar; Samira Kalayinia
Journal:  Eur J Med Res       Date:  2022-09-10       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.